Amgen Inc Among Leading Companies in the Male Infertility Pipeline Products Market | Globaldata Plc

June 23, 2022

Male infertility refers to a male's inability to achieve a pregnancy in a fertile female

/EIN News/ -- LONDON, June 23, 2022 (GLOBE NEWSWIRE) -- Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

Male infertility pipeline therapeutics constitutes close to 15 molecules. Out of these approximately 11 molecules are developed by companies and remaining by the universities/institutes.

The Male Infertility Drugs in Development market research report offered by GlobalData Plc provides comprehensive information on the therapeutics under development for male infertility (male health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for male infertility and features dormant and discontinued projects.

Male Infertility Pipeline Products Market Segmentation by Target

Male Infertility Pipeline Products Market Analysis by Target

For more target insights, download a free report sample

Male Infertility Pipeline Products Market Segmentation by Mechanisms of Action

Male Infertility Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Male Infertility Pipeline Products Market Segmentation by Routes of Administration

Male Infertility Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Male Infertility Pipeline Products Market Segmentation by Molecule Types

Male Infertility Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Leading Companies in the Male Infertility Pipeline Products Market

Male Infertility Pipeline Products Market Analysis by Leading Companies

To know more about leading companies, download a free report sample

Male Infertility Pipeline Products Market Overview

Targets Follicle Stimulating Hormone Receptor, Telomerase Reverse Transcriptase,
Androgen Receptor, Non-Lysosomal Glucosylceramidase, Phosphodiesterase 3, and Tumor Necrosis Factor Ligand Superfamily Member 11
Mechanisms of Action Follicle Stimulating Hormone Receptor Agonist, Telomerase Reverse Transcriptase Activator, Androgen Receptor Agonist, Non-Lysosomal Glucosylceramidase Replacement, Phosphodiesterase 3 Inhibitor, and Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor
Routes of Administration Intravenous, Oral, Subcutaneous, and Vaginal
Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Gene Therapy, Recombinant Enzyme, and Recombinant Protein
Leading Companies Amgen Inc, Aprilbio Co Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, cStem Regeneration Pharmaceutical Co Ltd, Ferring Pharmaceuticals Inc, Igyxos SA, Neuromagen Pharma Ltd, Park of Active Molecules, Prokrea BCN SL, and Reven Holdings Inc

Male Infertility Pipeline Products Market Report Scope

Reasons to Buy

FAQs

What are the key targets in the male infertility pipeline products market?
The key targets of the male infertility pipeline products market are Follicle Stimulating Hormone Receptor, Telomerase Reverse Transcriptase Androgen Receptor, Non-Lysosomal Glucosylceramidase, Phosphodiesterase 3, and Tumor Necrosis Factor Ligand Superfamily Member 11.

What are the key mechanisms of action in the male infertility pipeline products market?
Some of the key mechanisms of action of the male infertility pipeline products market are Follicle Stimulating Hormone Receptor Agonist, Telomerase Reverse Transcriptase Activator, Androgen Receptor Agonist, Non-Lysosomal Glucosylceramidase Replacement, Phosphodiesterase 3 Inhibitor, and Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor.

What are the key routes of administration in the male infertility pipeline products market?
The key routes of administration in the male infertility pipeline products market are intravenous, oral, subcutaneous, and vaginal.

What are the key molecule types in the male infertility pipeline products market?
The key molecule types in the male infertility pipeline products market are small molecule, monoclonal antibody, cell therapy, fusion protein, gene therapy, recombinant enzyme, and recombinant protein.

Which are the leading companies in the male infertility pipeline products market?
Some of the key companies in the male infertility pipeline products market are Amgen Inc, Aprilbio Co Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, cStem Regeneration Pharmaceutical Co Ltd, Ferring Pharmaceuticals Inc, Igyxos SA, Neuromagen Pharma Ltd, Park of Active Molecules, Prokrea BCN SL, and Reven Holdings Inc.

Related Reports

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts
GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400